Targovax submits a study of its adenovirus based immune therapy ONCOS-102 to the regulatory authorities in Spain
February 02, 2016 02:05 ET
|
Targovax ASA
OSLO, Norway, Feb. 2, 2016 (GLOBE NEWSWIRE) -- Targovax has submitted a study protocol to the regulatory authorities in Spain to assess its ONCOS-102 product in combination with chemotherapy in...
Targovax ASA: Interim report third quarter 2015
November 26, 2015 01:04 ET
|
Targovax ASA
Next development phase established via merger, capital increase and new partnerships
Merged with Finnish company Oncos Therapeutics in July, establishing a combined company with two promising...
Targovax ASA: Invitation to presentation of Targovax' third quarter 2015 results
November 19, 2015 03:23 ET
|
Targovax ASA
LYSAKER, Norway, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Targovax ASA (Targovax) will release its Q3 2015 results on Thursday November 26, 2015 at 07:00 CET. The quarterly report and the presentation...
Targovax ASA: LUDWIG CANCER RESEARCH AND CANCER RESEARCH INSTITUTE PARTNER WITH TARGOVAX TO TEST CANDIDATE VIROTHERAPY IN EARLY-PHASE CLINICAL TRIALS
November 18, 2015 08:18 ET
|
Targovax ASA
NEW YORK and OSLO, Norway, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Ludwig Cancer Research and the Cancer Research Institute (CRI) announced today an agreement with the biotechnology company Targovax to...
Targovax to present at upcoming investor Conferences
November 06, 2015 02:52 ET
|
Targovax ASA
OSLO, Norway, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Targovax ASA [TRVX.OTC] today announced that executives from the company will present at three investor conferences in the months of November and...
Targovax ASA: Immunotherapy with ONCOS-102 show potential to activate immunologically silent tumors and reduce local immune suppression in advanced tumors
November 05, 2015 07:40 ET
|
Targovax ASA
Lysaker, Norway, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Targovax [TRVX.OTC] will present at the SITC 2015 - an annual event of The Society for Immunotherapy of Cancer in Maryland, USA.
SITC is the world's...